AndreaBozzo/ceres-open-data-index huggingface dataset:
Poly purine.pyrimidine sequences upstream of the beta-galactosidase gene affect gene expression in

Background
          Poly purine.pyrimidine sequences have the potential to adopt intramolecular triplex structures and are overrepresented upstream of genes in eukaryotes. These sequences may regulate gene expression by modulating the interaction of transcription factors with DNA sequences upstream of genes.
        
        
          Results
          A poly purine.pyrimidine sequence with the potential to adopt an intramolecular triplex DNA structure was designed. The sequence was inserted within a nucleosome positioned upstream of the β-galactosidase gene in yeast, Saccharomyces cerevisiae, between the cycl promoter and gal 10Upstream Activating Sequences (UASg). Upon derepression with galactose, β-galactosidase gene expression is reduced 12-fold in cells carrying single copy poly purine.pyrimidine sequences. This reduction in expression is correlated with reduced transcription. Furthermore, we show that plasmids carrying a poly purine.pyrimidine sequence are not specifically lost from yeast cells.
        
        
          Conclusion
          We propose that a poly purine.pyrimidine sequence upstream of a gene affects transcription. Plasmids carrying this sequence are not specifically lost from cells and thus no additional effort is needed for the replication of these sequences in eukaryotic cells.
Patent AT-E399592-T1: [Translated] HYDROTHERMICALLY STABLE, METAL-DOPED ZEOLITE BETA FOR THE REDUCTION OF NOX

The present invention is directed to an iron-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the iron-promoted zeolite beta is treated so as to provide increased amounts of the iron promoter in the form of Fe(OH).The stabilized zeolite is formed by cation exchange of an iron salt into a zeolite beta which has a reduced sodium content such as by exchanging a sodium beta with ammonium or hydrogen cations. A zeolite beta having a reduced carbon content and a Si/Al ratio of no more than 10 also increases the Fe(OH) content of the iron-promoted catalyst. The iron-promoted catalyst has the iron in the form of Fe(OH).
California: 2011-2012 NSDUH

This report presents California\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 525517: 2-(3-Chloro-4-benzyloxy-phenyl)-propionic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(3-chloro-4-phenylmethoxyphenyl)propanoate. Molecular Formula: C17H17ClO3. Molecular Weight: 304.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NCHS Synthetic Linked 2018 NHIS-HUD-CMS Data

To make linked data easier to access, NCHS has piloted a project that creates synthetic linked data files. Synthetic data are created using statistical techniques to maintain properties of the original data. This synthetic linked file includes selected variables from the 2018 National Health Interview Survey (NHIS) with selected linked data from the Centers for Medicare and Medicaid Services (CMS) Medicare health insurance records and participation in the Department of Housing and Urban Development (HUD) federal housing assistance programs.
State and Substate Estimates of Any Mental Illness from the 2012–2014 National Surveys on Drug Use and Health

This report provides state and substate estimates of any mental illness among adults aged 18 or older using combined 2012-2014 National Survey on Drug Use and Health data. Estimates are provided for the nation as a whole and for each state and substate areas. Comparisons are made to estimates from 2010–2012.
Pulse pressure and age at menopause

Background
          The objective of this study was to study the association of early age at menopause with pulse pressure (PP), a marker of arterial stiffness, and PP change.
        
        
          Methods
          The effect of natural menopause was studied in 2484 women from the Atherosclerosis Risk in Communities (ARIC) Study who had not used hormone replacement therapy and who had not had a hysterectomy. The cross-sectional association of age with PP was evaluated in the entire cohort. The cross-sectional association of recalled age at menopause was evaluated in the 1688 women who were postmenopausal at baseline. PP change over 6 years was assessed in relation to menopausal age separately in women who were postmenopausal at baseline and in those whose menopause occurred during the 6-year interval.
        
        
          Results
          Chronological age was strongly and positively associated with PP in cross-sectional analyses, but not independently associated with PP change. While menopausal age was not associated cross-sectionally with PP, early age at menopause (age<45) was significantly and independently associated with a slightly larger increase in PP (8.4, 95% CI 7.0–9.8) than later menopause (6.5, 95% CI 5.8;7.2). However, among normotensive women the difference was not statistically significant (p = 0.07, 6.1 vs 4.7).
        
        
          Conclusions
          Early age at menopause may be related to a greater increase in arterial stiffness, but the effect appears to be small and further evidence is needed.
Landiolol

Rapibylk (landiolol hydrochloride) is an intravenous prescription medication used as a beta-blocker to help control rapid heart rate. It comes as a lyophilized powder in a single-dose vial, equivalent to 280 mg of landiolol base, manufactured by AOP Orphan Pharmaceuticals GmbH. This information was generated using AI and is provided for informational and research purposes only.
Compound 528977: 1,2-Heptacosanediol, di-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl(1-trimethylsilyloxyheptacosan-2-yloxy)silane. Molecular Formula: C33H72O2Si2. Molecular Weight: 557.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400084-T1: [Translated] HARD MOUNTED MULTIPLE RESONATOR ACOUSTIC BULK WAVE FILTER WITH A PATTERNED ACOUSTIC MIRROR

A method of fabricating a mufti-resonator bulk acoustic wave (BAW) filter and a filter provided by such a method, the filter having a plurality of layers of materials serving as an acoustic mirror for a plurality of resonator sections, each resonator section including at least a top electrode and a bottom electrode sandwiching a piezolayer, the method including the steps of: choosing dielectric materials for some of the layers of materials serving as the acoustic mirror and metallic materials for the others of the layers; and providing at least one of the metallic layers via a fabrication procedure in which the metallic layer is patterned into distinct portions by an etching process that removes enough of the metallic layer between where different resonator sections are to be placed as to provide electrical isolation between the portions of the layer beneath the different resonator sections; thereby providing a multi-resonator BAW filter with reduced capacitive coupling between resonators, compared to the capacitive coupling present in a multi-resonator BAW filter fashioned in a similar manner except excluding the step of etching to pattern any metallic layers of the similarly fashioned acoustic mirror. <IMAGE>
Compound 529397: 2-Methylthiolan-4-one-3-thiol

Chemical compound data from PubChem database. IUPAC Name: 5-methyl-4-sulfanylthiolan-3-one. Molecular Formula: C5H8OS2. Molecular Weight: 148.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401399-T1: [Translated] NUCLEIC ACID FOR A CLONING VECTOR

The invention concerns a nucleic acid forming part of a cloning vector or designed to be inserted in a cloning vector. Said nucleic acid comprises at least a functional nucleotide sequence, which is needed for cloning and/or expression and is coupled with at least one sequence for identifying type II restriction endo nucleases (REII), so that the cleavage site of the REII concerned is inside said functional nucleotide sequence. The invention also relates to a method using said nucleic acid.
Patent AT-E401666-T1: [Translated] LIGHT DETECTING DEVICE

A method of fabricating light-sensing devices including photodiodes monolithically integrated with CMOS devices. Several types of photodiode devices (PIN, HIP) are expitaxially grown in one single step on active areas implanted in a common semiconductor substrate, the active areas having defined polarities. The expitaxially grown layers for the photodiode devices may be either undoped or in-situ doped with profiles suitable for their respective operation. With appropriate choice of substrate materials, device layers and heterojunction engineering and process architecture, it is possible to fabricate silicon-based and germanium-based multi-spectral sensors that can deliver pixel density and cost of fabrication comparable to the state of the art CCDs and CMOS image sensors. The method can be implemented with epitaxially deposited films on the following substrates: Silicon Bulk, Thick-Film and Thin-Film Silicon-On-Insulator (SOI), Germanium Bulk, Thick-Film and Thin-Film Geranium-On-Insulator (GeOI).
Compound 528060: L-Isoleucine, N-(tert-butyldimethylsilyl)-, tert-butyldimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[[tert-butyl(dimethyl)silyl]amino]-3-methylpentanoate. Molecular Formula: C18H41NO2Si2. Molecular Weight: 359.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529241: Oxetane, 3-bromomethyl-3-[2-methyl-1-(3-methylphenyloxy)propyl]

Chemical compound data from PubChem database. IUPAC Name: 3-(bromomethyl)-3-[2-methyl-1-(3-methylphenoxy)propyl]oxetane. Molecular Formula: C15H21BrO2. Molecular Weight: 313.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase

Background
          Epstein-Barr virus (EBV) infects resting B-lymphocytes and transforms them into immortal proliferating lymphoblastoid cell lines (LCLs) in vitro. The transformed immunoblasts may grow up as immunoblastic lymphomas in immuno-suppressed hosts.
        
        
          Results
          In order to identify cellular protein targets that may be involved in Epstein-Barr virus mediated B-cell transformation, human LCL cDNA library was screened with one of the transformation associated nuclear antigens, EBNA-3 (also called EBNA-3A), using the yeast two-hybrid system. A clone encoding a fragment of a novel human protein was isolated (clone 538). The interaction was confirmed using in vitro binding assays. A full-length cDNA clone (F538) was isolated. Sequence alignment with known proteins and 3D structure predictions suggest that F538 is a novel human uridine kinase/uracil phosphoribosyltransferase. The GFP-F538 fluorescent fusion protein showed a preferentially cytoplasmic distribution but translocated to the nucleus upon co-expression of EBNA-3. A naturally occurring splice variant of F538, that lacks the C-terminal uracil phosphoribosyltransferase part but maintain uridine kinase domain, did not translocate to the nucleus in the presence of EBNA3. Antibody that was raised against the bacterially produced GST-538 protein showed cytoplasmic staining in EBV negative Burkitt lymphomas but gave a predominantly nuclear staining in EBV positive LCL-s and stable transfected cells expressing EBNA-3.
        
        
          Conclusion
          We suggest that EBNA-3 by direct protein-potein interaction induces the nuclear accumulation of a novel enzyme, that is part of the ribonucleotide salvage pathway. Increased intranuclear levels of UK/UPRT may contribute to the metabolic build-up that is needed for blast transformation and rapid proliferation.
2011 CMHS Uniform Reporting System (URS) Output Tables for Minnesota

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 529414: Tricyclo[3.3.1.1(3.7)]decane

Chemical compound data from PubChem database. IUPAC Name: 3-ethylbicyclo[3.3.1]nonane. Molecular Formula: C11H20. Molecular Weight: 152.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Positivity Percentage by Jurisdiction, 7-Day Average

<b>NOTE:</b> This dataset is no longer being updated as of 4/27/2023.
It is retired and no longer included in public COVID-19 data dissemination.

See this link for more information
https://imap.maryland.gov/pages/covid-data

<b>Summary</b>
The 7-day average percent positive rate for COVID-19 tests administered in each Maryland jurisdiction.

<b>Description</b>
The 7-day percent positive rate is a rolling average of each day’s positivity percentage. The percentage is calculated using the total number of tests electronically reported to MDH (by date of report) and the number of positive tests electronically reported to MDH (by date of report). Electronic lab reports from NEDDSS.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patent AT-E400604-T1: [Translated] CROSSLINKING OF RESINS

A method of effecting cross-linking of a resin comprises generating vinyl sulfonyl moieties in situ with the resin, said sulfonyl moieties then undergoing a reaction which effects cross-linking of the resin. The vinyl sulfonyl moieties may be generated as a result of a loss of a liquid carrier for the resin to be cross-linked. The cross-linking reaction may result from reaction of the vinyl sulfonyl moieties with nucleophilic groups in the resin composition. The resin may be a co-polymer of a compound of formula (IV) with other olefinically unsaturated monomers.
A human RNA polymerase II subunit is encoded by a recently generated multigene family

Background
          The sequences encoding the yeast RNA polymerase II (RPB) subunits are single copy genes.
        
        
          Results
          While those characterized so far for the human (h) RPB are also unique, we show that hRPB subunit 11 (hRPB11) is encoded by a multigene family, mapping on chromosome 7 at loci p12, q11.23 and q22. We focused on two members of this family, hRPB11a and hRPB11b: the first encodes subunit hRPB11a, which represents the major RPB11 component of the mammalian RPB complex ; the second generates polypeptides hRPB11bα and hRPB11bβ through differential splicing of its transcript and shares homologies with components of the hPMS2L multigene family related to genes involved in mismatch-repair functions (MMR). Both hRPB11a and b genes are transcribed in all human tissues tested. Using an inter-species complementation assay, we show that only hRPB11bα is functional in yeast. In marked contrast, we found that the unique murine homolog of RPB11 gene maps on chromosome 5 (band G), and encodes a single polypeptide which is identical to subunit hRPB11a.
        
        
          Conclusions
          The type hRPB11b gene appears to result from recent genomic recombination events in the evolution of primates, involving sequence elements related to the MMR apparatus.
CDC STATE System Tobacco Legislation - Smokefree Indoor Air

1995-2024. Centers for Disease Control and Prevention (CDC).  State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation – Smokefree Indoor Air. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to state legislation on smokefree indoor air in areas such as: Bars, Commercial Day Care Centers, Government Multi-Unit Housing, Government Worksites, Home-Based Day Care Centers, Hotels and Motels, Personal Vehicles, Private Multi-Unit Housing, Private Worksites, Restaurants, Bingo Halls, Casinos, Enclosed Arenas, Grocery Stores, Hospitals, Hospital Campuses, Malls, Mental Health Outpatient and Residential Facilities, Prisons, Public Transportation, Racetrack Casinos, Substance Abuse Outpatient and Residential Facilities.
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets, 5 mg,cll

This generic medication, approved under ANDA207388 by Alvogen Inc., contains a combination of amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate) in oral tablet form. It's a Schedule II controlled substance, available in strengths equivalent to 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg of amphetamine, used as a central nervous system stimulant. This information was generated using AI and is provided for informational and research purposes only.
Compound 525116: 3-Chloropropyl isobutyrate

Chemical compound data from PubChem database. IUPAC Name: 3-chloropropyl 2-methylpropanoate. Molecular Formula: C7H13ClO2. Molecular Weight: 164.63. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Comprehensive Child Welfare Information System (CCWIS) and Software Bills of Materials (SBOMs)

This Information Memorandum (IM) provides title IV-E agencies that choose to develop a CCWIS with information on SBOMs.  Agencies can use SBOMs to enhance CCWIS security by supporting source code integrity and software supply chain security.  This IM provides information and resources applicable to federal information technology (IT) procurements.  While the Children’s Bureau (CB) does not currently require a SBOM for state and tribal CCWIS procurements, we strongly encourage title IV-E agencies to require a SBOM with CCWIS procurements and contracts to increase IT security.

Metadata-only record linking to the original dataset. Open original dataset below.
4.12a Facilities offering services in sign language for the hearing impaired and in languages other than English, by facility operation and primary focus of facility: 2010. Numberv

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facilities offering services in sign language for the hearing impaired and in languages other than English, by facility operation and primary focus of facility in 2010. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Patent AT-E400665-T1: [Translated] SGK AND NEDD AS DIAGNOSTIC AND THERAPEUTIC TARGETS

The invention relates to the use of a substance for the diagnostic detection of Sgk, especially Sgk1 and/or Sgk3, and/or PKB and/or Nedd, especially Nedd4-2, and to the use of active ingredients which influence glucose transport for treating diseases associated with disturbed glucose transport, and for fattening animals. The invention also relates to a diagnosis kit and a pharmaceutical composition comprising an active quantity of at least one active ingredient which influences glucose transport. The invention further relates to a method for producing transgenic animals.
2018-2020 NSDUH Substate Region Definitions

Substate estimates for these years are no longer available due to methodological concerns with combining 2020 data with data from 2018 and 2019. We apologize for any inconvenience or confusion this may cause.Because of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the three years could be misleading.For more detail on this decision, see the 2018-2020substate data page.
Affordability Most Frequent Reason for Not Receiving Mental Health Services (2009 to 2011 NSDUH)

This report uses 2009 to 2011 National Survey on Drug Use and Health (NSDUH) to assess reasons for not receiving mental health services among adults aged 18 or older with an unmet need for mental health care. Reasons for not getting care included cost/insurance, low perceived need; structural barriers; stigma; and thinking services would not help. Results are shown by age group.